[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2477648T3 - Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych - Google Patents

Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych

Info

Publication number
PL2477648T3
PL2477648T3 PL10817793.2T PL10817793T PL2477648T3 PL 2477648 T3 PL2477648 T3 PL 2477648T3 PL 10817793 T PL10817793 T PL 10817793T PL 2477648 T3 PL2477648 T3 PL 2477648T3
Authority
PL
Poland
Prior art keywords
therapy
synergistic anti
hematologic cancers
hematologic
cancers
Prior art date
Application number
PL10817793.2T
Other languages
English (en)
Inventor
Irving L. Weissman
Ravindra Majeti
Arash Ash Alizadeh
Mark P. Chao
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43758999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2477648(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL2477648T3 publication Critical patent/PL2477648T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10817793.2T 2009-09-15 2010-09-15 Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych PL2477648T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27672609P 2009-09-15 2009-09-15
PCT/US2010/048992 WO2011034969A1 (en) 2009-09-15 2010-09-15 Synergistic anti-cd47 therapy for hematologic cancers

Publications (1)

Publication Number Publication Date
PL2477648T3 true PL2477648T3 (pl) 2022-11-07

Family

ID=43758999

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10817793.2T PL2477648T3 (pl) 2009-09-15 2010-09-15 Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych

Country Status (9)

Country Link
US (4) US8758750B2 (pl)
EP (2) EP4134095A1 (pl)
AU (1) AU2010295661B2 (pl)
CA (2) CA3057650A1 (pl)
ES (1) ES2927646T3 (pl)
PL (1) PL2477648T3 (pl)
PT (1) PT2477648T (pl)
SI (1) SI2477648T1 (pl)
WO (1) WO2011034969A1 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043181B1 (en) * 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
WO2009091601A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by cd47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
ME03512B (me) * 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
JP6392770B2 (ja) * 2012-12-03 2018-09-19 ノビミューン エスアー 抗ｃｄ４７抗体およびその使用方法
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP2968536B1 (en) * 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
WO2016022971A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
EP3656869B1 (en) * 2014-08-26 2020-11-11 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
EP3204420B1 (en) 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
CA2967834C (en) 2014-12-05 2024-01-16 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
BR112017019856A2 (pt) * 2015-03-18 2018-05-29 Memorial Sloan Kettering Cancer Center composições e métodos para tratar leucemias mieloides agudas e síndromes mielodisplásicas
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
ES2970186T3 (es) * 2015-11-25 2024-05-27 Immunogen Inc Formulaciones farmacéuticas y métodos de uso de las mismas
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
US10946042B2 (en) * 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
WO2017121771A1 (en) 2016-01-11 2017-07-20 Blink Biomedical Sas Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
CN109071676A (zh) * 2016-01-21 2018-12-21 小利兰·斯坦福大学托管委员会 使用免疫调节剂的组合的癌症治疗
AU2017250029C1 (en) * 2016-04-15 2022-03-24 Pfizer Inc. Macrophage stimulation in CD47 blockade therapy
JP7160683B2 (ja) 2016-04-29 2022-10-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 術後癒着の予防及び治療のための方法及び組成物
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
EP3494228B1 (en) * 2016-08-03 2021-07-07 CBmed GmbH Center for Biomarker Research in Medicine Method for prognosing and diagnosing tumors
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
BR112019005333A2 (pt) 2016-09-21 2019-06-11 Aptevo Research And Development Llc proteínas de ligação a cd123 e composições e métodos relacionados
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3345924A1 (en) 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
WO2018237168A1 (en) * 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University DOSING PARAMETERS FOR CD47 TARGETING THERAPIES WITH HEMATOLOGICAL MALIGNANCIES
WO2019027903A1 (en) 2017-08-02 2019-02-07 Phanes Therapeutics, Inc. ANTI-CD47 ANTIBODIES AND USES THEREOF
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
US11802153B2 (en) 2017-10-18 2023-10-31 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
WO2019086574A1 (en) * 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 and cd33 antigen-binding molecules
AU2018358004A1 (en) 2017-11-01 2020-05-28 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules
SI3752190T1 (sl) 2018-02-12 2022-11-30 Forty Seven, Inc. Shema zdravljenja proti raku z uporabo protiteles proti CD47 in proti CD20
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
BR112021000637A2 (pt) * 2018-07-17 2021-04-13 The Regents Of The University Of California Célula cardíaca hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença cardíaca, método para produzir uma população de células cardíacas hipoimunes, célula endotelial hipoimune isolada, método para tratar um paciente que sofre de uma afecção ou doença vascular, método para produzir uma população de células endoteliais hipoimunes, neurônio dopaminérgico hipoimune isolado, método para tratar um paciente que sofre de uma doença ou afecção neurodegenerativa, método para produzir uma população de neurônios dopaminérgicos hipoimunes, célula de ilhota pancreática hipoimune isolada, método para tratar um paciente que sofre de diabetes, método para produzir uma população de células de ilhota pancreática hipoimunes, célula de epitélio pigmentado da retina (rpe) hipoimune isolada, método para tratar um paciente que sofre de uma afecção ocular, e método para produzir uma população de células de epitélio pigmentado da retina (rpe) hipoimunes
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
CA3118312A1 (en) * 2018-10-29 2020-05-07 Tigatx, Inc. Compositions and methods comprising iga antibody constructs
KR20210094610A (ko) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
JP2022552748A (ja) * 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
CN110755635B (zh) * 2019-11-14 2022-10-11 天津大学 Flu@α-cd47@RGD制剂的合成方法
IL293463A (en) * 2019-12-05 2022-07-01 Sorrento Therapeutics Inc Compositions and methods comprising an anti-cd47 antibody in combination with a tumor-directed antibody
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
WO2023287803A2 (en) * 2021-07-15 2023-01-19 Vcreate, Inc. Compositions and methods for making novel t-cell receptors
WO2023165618A1 (en) * 2022-03-04 2023-09-07 Nanjing University Methods for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
CN1173878A (zh) 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2003072036A2 (en) * 2002-02-21 2003-09-04 Duke University Treatment methods using anti-cd22 antibodies
US20050180972A1 (en) * 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
WO2005044857A1 (ja) 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha ヒト化抗cd47抗体
WO2007053189A2 (en) 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
EP2139922A1 (en) 2007-03-28 2010-01-06 Biogen Idec, Inc. Treatment of hodgkins lymphoma
WO2009091601A1 (en) * 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by cd47
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system

Also Published As

Publication number Publication date
EP2477648B1 (en) 2022-07-20
US20120282174A1 (en) 2012-11-08
EP4134095A1 (en) 2023-02-15
CA3057650A1 (en) 2011-03-24
AU2010295661B2 (en) 2015-04-30
AU2010295661A1 (en) 2012-03-22
US20210214437A1 (en) 2021-07-15
US8758750B2 (en) 2014-06-24
EP2477648A1 (en) 2012-07-25
ES2927646T3 (es) 2022-11-08
US20190048075A1 (en) 2019-02-14
SI2477648T1 (sl) 2022-09-30
CA2771336C (en) 2019-11-26
CA2771336A1 (en) 2011-03-24
PT2477648T (pt) 2022-10-27
US20140369924A1 (en) 2014-12-18
EP2477648A4 (en) 2013-05-08
WO2011034969A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
PL2477648T3 (pl) Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
HK1200363A1 (en) Compounds useful for treating cancer
HK1175476A1 (en) Cancer treatment
HK1197036A1 (en) Combination therapy for copd copd
IL206654A0 (en) Combination therapy
PL2440287T3 (pl) Urządzenie do terapii fotodynamicznej
HK1174571A1 (en) Combination therapy for copd copd
EP2506875A4 (en) METHOD FOR THE TREATMENT OF TUMORS WITH K-RAS MUTATIONS
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
HUE038611T2 (hu) Vitiligo terápia
GB201013898D0 (en) Well treatment
GB0901465D0 (en) Compounds for use in therapy
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0916997D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0707556D0 (en) Treatment for cancer
GB0809046D0 (en) Cancer treatment
GB0907973D0 (en) Combination therapy
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy
GB0901497D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy
GB0914441D0 (en) Compound for therapy
GB0903321D0 (en) Therapy
GB0921244D0 (en) Therapy